*Disseminated on Behalf of Imunon, Inc
What if your body’s immune system could be taught to fight cancer at the tumor site?
What if your immune system created a vaccine response that protected against infectious diseases without needing a virus or device to deliver it?
Recent data helped earn FDA Fast Track and Orphan Drug status (US and EU) and is now being tested in OVATION-3, a 500-patient Phase 3 registrational trial with overall survival as the primary endpoint
IMNN Has Less Than 4M in the Float According to Finviz
Hello Everyone,
We have another company that is brand new to our members we want you to research for today’s session. This one has an excitingly low float of under 4 Million shares according to Finviz.
This is not a catalyst to be overlooked. We all know what can happen when these low float Nasdaq listed companies if momentum kicks in.
The merits of the company itself are encouraging as well. We have looked at hundreds of Biotechs over the past 10 years. It is rare to find one that has an active Phase III trial. The results of the studies thus far have been what the company is looking for and the numbers have been in the companies favor as they move forward.
IMUNON (Nasdaq: IMNN) is a clinical-stage biotech tackling one of oncology’s more stagnant corners: frontline treatment for advanced ovarian cancer, a standard of care that hasn’t meaningfully changed in 30-plus years and where no immunotherapy has ever shown a strong survival benefit.
Its approach is TheraPlas®, a non-viral DNA plasmid platform that delivers therapeutic genes straight into tumors. The lead candidate, IMNN-001, encodes IL-12 and is injected directly into the abdominal cavity to turn an immunologically “cold” tumor “hot.” In a randomized Phase 2 trial (OVATION-2), it produced a 14.7-month median overall survival improvement over chemo alone — jumping to 24.2 months in patients also on PARP inhibitor maintenance. That data helped earn FDA Fast Track and Orphan Drug status (US and EU) and is now being tested in OVATION-3, a 500-patient Phase 3 registrational trial with overall survival as the primary endpoint. Dosing began Q3 2025, with full enrollment targeted for roughly Q1 2029.
New preliminary data, from a minimal residual disease (MRD) sub-study of that same Phase 2 program run with MD Anderson and Break Through Cancer, adds another encouraging signal: a lower MRD-positive rate with IMNN-001 (44% vs. 67% control), higher ctDNA clearance (87.5% vs. 62.5%), and a 100% no-evidence-of-disease rate at second-look surgery vs. 56% in control — alongside a clean safety profile, with no cytokine release syndrome or serious immune-related adverse events reported. The catch: this is a tiny readout, just nine patients per arm at the primary endpoint, not statistically powered, and explicitly described as preliminary and directional. The PARP inhibitor subgroup finding is similarly hypothesis-generating rather than randomized. Still, it echoes the OVATION-2 survival signal and adds another data point supporting the bet now riding on OVATION-3 — the trial that will actually determine whether this benefit holds up at scale.
What if your body’s immune system could be taught to fight cancer at the tumor site?
What if your immune system created a vaccine response that protected against infectious diseases without needing a virus or device to deliver it?
Most of us know DNA as the building block of life. It codes for everything, for all the proteins in our bodies.
At Imunon, they are pioneering the use of DNA as a therapeutic that codes for proteins which our body then uses to produce medicine where you need it, for as long as you need it.
The IMUNON team is pioneering technologies that provide the foundation for a range of therapeutics for common, difficult-to-treat forms of cancer as well as technologies for the development of DNA vaccines against infectious diseases.
TheraPlas™
TheraPlas™ is a novel, nonviral delivery system for the development of immunotherapies and other anti-cancer nucleic acid-based therapies.
They are bringing it to market focused on aggressive, hard to treat cancers, starting with advanced ovarian cancer.
There are 300,000 new diagnoses of Epithelial ovarian cancer (EOC) per year globally, 20,000 patients in the US alone, with 70% of diagnoses occurring in the late stage and a high recurrence rate.
Their IMNN-001 product is built on the TheraPlas™ platform, and targets the micro-environement of ovarian cancer via local production of safe and durable levels of a powerful anti-cancer immune agent, IL-12.
PlaCCine
PlaCCine is a novel platform for the development of nucleic acid vaccines for infectious diseases and cancer that leverages a multivalent approach and non-viral DNA technology to generate a robust humoral immune response as well as a robust and durable T-cell response.
More than 80 pathogenic viruses have been discovered since 1980, but less than 4% have a vaccine commercially available.
That’s where the PlaCCine platform comes in…
Their team is developing an array of prophylactic vaccines, with strong evidence of immunogenicity and durability of protection.
NEWS
Jun 23, 2026
IMUNON to Present at the Life Sciences Investor Forum on June 25th
Jun 22, 2026
IMUNON Announces Up to $10 Million Cash Financing
Jun 4, 2026
IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
May 5, 2026
Mar 31, 2026
Mar 25, 2026
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
Mar 24, 2026
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
Feb 5, 2026
Dec 30, 2025
MANAGEMENT
Stacy R. Lindborg, Ph.D.
President, Chief Executive Officer & Board Director
Stacy R. Lindborg, PhD, was appointed President and Chief Executive Officer of Imunon in May 2024. Dr. Lindborg has served on Imunon’s Board of Directors since June 2021. Dr. Lindborg has nearly 30 years of pharmaceutical and biotech industry experience with a particular focus on R&D, regulatory affairs, executive management and strategy development. She has designed, hired and led global teams, guiding long-term vision for growth through analytics and stimulating innovative development platforms to increase productivity. Prior to joining Imunon, Dr. Lindborg was Executive Vice President and Co-Chief Executive Officer at BrainStorm Cell Therapeutics where she will remain a member of the company’s Board of Directors. At BrainStorm she was accountable for creating and executing clinical development strategies through registration and launch and progressed its novel cell therapy for ALS through a positive Phase 3 Special Protocol Assessment (SPA) study with the U.S. Food and Drug Administration. She interacted frequently with investors and analysts, represented the company in the scientific community as well as with the media, and played an active role in discussions with potential business partners.
Douglas V. Faller, MD, PhD
Chief Medical Officer
Dr. Faller, an internationally recognized oncologist/hematologist and scientist, has nearly 30 years of pharmaceutical and biotech industry experience with a particular focus on clinical R&D, discovery, regulatory affairs, and strategy development. He has worked with small molecules, gene therapies, biologics and cell therapies to address a range of malignant and non-malignant diseases and disorders, including rare and genetic diseases, and neurological and neuropsychiatric disorders. He has extensive experience in early-stage development as well as global late-stage development and world-wide marketing approvals. He has taken molecules (including those discovered in his own academic laboratories) from first-in-human studies in the clinic, through registrational trials, international regulatory approvals and commercial launch. Prior to his position with the Company, Dr. Faller served as Chief Medical Officer of Skyhawk Therapeutics beginning in 2024, where he led the development of splicing modulators for the treatment of oncological and neurological disorders. From 2022 through 2024, he served as Chief Medical Officer of Oryzon Genomics, leading the development of epigenetic-modifying small molecules in oncology and neuropsychiatric disorders, and prior to that role, from 2015 through 2022, Dr. Faller was Executive Medical Director at Takeda Pharmaceuticals, where he led multiple programs in hematologic oncology, solid tumor malignancies and rare diseases, from first-in-human to global registrational trials and post-marketing trials. He was also extensively involved in Business Development for oncology, hematology and rare diseases. Dr. Faller was the scientific founder and CMO/CSO of Viracta Therapeutics, which he joined in 2019 and remained through 2021, after it became publicly traded and launched a pivotal trial of his therapeutic. Dr. Faller is the scientific founder or co-founder of four biopharma companies. Prior to working full-time in the biopharmaceutical industry, Dr. Faller was a professor at Harvard Medical School, and an attending physician at Brigham and Women’s Hospital, Boston Children’s Hospital and Dana-Farber Cancer Institute. He founded and directed the Comprehensive Cancer Center at Boston University, where he also served as the first Grunebaum Professor for Cancer Research, Vice-Chairman of the Department of Medicine, and Professor of Medicine, Biochemistry, Pediatrics, Microbiology, Pathology and Laboratory Medicine. Dr. Faller received a B.S. in biochemistry from the Massachusetts Institute of Technology, an MD from Harvard Medical School, and a PhD from the Massachusetts Institute of Technology in cancer molecular biology. He has authored more than 300 abstracts, 230 presentations and 375 manuscripts that have been published in peer-reviewed journals. He is certified in Internal Medicine, Hematology and Oncology, and is a Fellow of the American College of Physicians.
Josh Blacher
interim chief financial officer
Mr. Blacher currently serves as Interim Chief Financial Officer of Imunon, Inc. He has been an employee of Danforth Advisors since September 2022, where he has served as interim chief financial officer in a consulting capacity for numerous public life sciences companies. Prior to joining Danforth Advisors, Mr. Blacher served as Chief Business Officer at InMed Pharmaceuticals (Nasdaq: INM) from April 2018 to August 2019, as Chief Financial Officer of Therapix Biosciences (Nasdaq: TRPX) from April 2017 to April 2018, and as Chief Financial Officer at Galmed Pharmaceuticals (Nasdaq: GLMD) from October 2014 to March 2017. Earlier in his career, Mr. Blacher held senior positions at Teva Pharmaceuticals, Deutsche Asset Management, and Morgan Stanley. Mr. Blacher holds a Bachelor of Arts in Economics from Yeshiva University and a Master of Business Administration in Finance from Columbia Business School.
Kristin Longobardi, MBA
Senior Vice President, strategic operations
Kristin Longobardi was appointed Sr. Vice President, Strategic Operations for Imunon in October of 2024. She comes to Imunon with over 25 years of pharmaceutical and biotech experience driving process optimization and efficiency, portfolio management, financial planning and analytics, and operational strategy development. Prior to Imunon, Ms. Longobardi held a variety of leadership positions at Biogen for over 20 years, most recently, Vice President, Quality Operations and Performance responsible for driving global R&D quality and compliance, operational productivity, alliance management, and executional efficiencies. Prior to that, she was a Sr. Director of Business and Financial Operations first for Biogen Clinical Operations and then for all of R&D, spanning from 2009 to 2016. Before then, she was in Corporate Finance at Biogen. Ms. Longobardi began her career as a scientist at Genome Therapeutics working on DNA sequencing and analysis for the Human Genome Project and other microbial pathogens for drug development and diagnostics. Ms. Longobardi received a Bachelor of Science from Bucknell University and an MBA from Babson College.
SINCERELY,
DISCLAIMER
MicroCapAlerts.io is owned by Dedicated Investors, LLC who is a publisher (the “Publisher”) of favorable information (the “Information”) about publicly traded companies (collectively the “Issuers”) listed on the NASDAQ Stock Exchange (“NASDAQ”), New York Stock Exchange (“NYSE”) and the OTC Markets is a paid advertisement. The Publisher lists its specific compensation at the bottom of this Disclaimer.
The Persons who pay us (“Paying Party”) to publish the Information and their affiliates may hold and control a significant amount of the public float and believe that if potential investors receive favorable information about the Issuers, investors will purchase the Issuers’ shares, including the shares that the Paying Party wants to sell. The Information is neither a solicitation to buy nor an offer to sell securities. The Information is not intended to be used as a source of information for making an investment decision. The Information is not intended and should not be used for trading or investment purposes.
Because the Publisher is paid to disseminate the Information to the public, the Publisher is required by the securities laws, including Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose certain information to you regarding its compensation, including the nature and amount of compensation. The Paying Party and its affiliates may engage in buying and selling of the Issuers’ securities before, during and after the Publication of the Information.
The Information provides de minimis information about the Issuers and is only a brief favorable snapshot of the Issuers subject to the Information. The Information consists of only positive content and does not include any negative information about the Issuers whatsoever; accordingly, you should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. The Publisher is not liable for your use of the Information or any success or failure that is directly or indirectly related to your use of the Information, including misinformation, omissions, errors or delays in providing or updating the Information, or for any actions taken by third parties in reliance upon the Information.
The Publisher is not objective or independent, and its publishing of the Information involves actual and material conflicts of interest, including: (i) the Publisher is paid to publish favorable information about the Issuers; (ii) the Publisher does not publish negative information because it is not paid to do so; and (iii) the Publisher is paid to publish the (favorable) Information about the Issuers advising others, including you, to purchase the Issuers’ securities; and while doing so, the Paying Party may plan to sell their shares of the Issuers.
The Information published by the Publisher may recommend that investors buy the Issuers’ shares while the Paying Party and/or their affiliates sell their shares of the Issuers. When the Paying Party sells their shares, the Issuers’ stock price may decline and thereby dramatically reduce the price at which investors can sell their shares. As such, investors who purchase the Issuers’ shares during the Publication of the Information will likely pay inflated prices. The Paying Party may sell the Issuers’ securities for less than the target prices set forth in the Information. The Paying Party and its affiliates may make substantial profits by selling their securities during the Publication of the Information while investors experience losses.
The Publisher makes no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability, and disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the information is at your own risk. The Information is provided “as is” without any warranties of any kind without limitation. The Publisher does not verify or confirm any portion of the Information and does not conduct any due diligence or research on any aspect of the Information, including the completeness, accuracy, truthfulness or reliability of the Information.
Investors should not rely upon the Information for any purpose and should contact a licensed investment advisor and their legal advisor and review all documents about the Issuers with the assistance of such advisors, including documents publicly filed on www.sec.gov and http://www.OTCMarkets.com to obtain information about the Issuers.
Before investing in any public company, you should conduct your own in-depth investigation with the assistance of your legal, tax and investment advisors of the Issuers’ financial condition, operations, management, products or services, trends in the industry, the Issuers’ trading history, short sale positions and risks that may be material to its business and other information you and your advisors deem material to an investment decision. This investigation should include, but not be limited to, a review of available public sources and information you receive directly from http://www.OTCMarkets.com and www.sec.gov.
The Publisher is not and does not act in the capacity of any of the following and is not qualified to do so; as such, you should not construe the Publisher’s activities as involving any of the following:
▪ An independent advisor or consultant;
▪ Providing investment advice or acting in the capacity of an investment adviser or engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
▪ Broker-dealer activities or acting in the capacity of a registered representative or broker;
▪ Stock picker;
▪ Securities trading expert;
▪ Securities researcher or analyst;
▪ Financial planner or financial planning;
▪ Provider of stock recommendations;
▪ Provider of advice about buying and selling or holding recommendations as to specific securities; or
▪ Making an offer or sale of securities or solicitation to purchase securities.
An investment in the Issuers involves a high degree of risk and uncertainties and may be subject to extreme volume and price volatility, especially during the Publication of the Information. Favorable past performance of the Issuers does not guarantee future results. If you purchase the securities of the Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Issuers include but are not limited to the risks stated below.
▪ The Information is not a solicitation or recommendation to buy, sell or hold securities, and the Publisher does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. The Publisher conducts no due diligence or investigation of the Information or the Issuers and does not receive any verification from any party regarding the Information.
▪ If the Publisher publishes any percentage gain of the Issuers’ share from the previous day’s close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
▪ The Information may contain statements that Issuers’ stock price has increased over a certain period of time, which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon such information in your analysis of the present or future potential of the Issuers or its securities.
▪ The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Issuers’ future stock price or future financial performance.
▪ You may encounter difficulties determining what, if any, portions of the Information are material or nonmaterial, making it all the more imperative that you conduct your own independent investigation of the Issuers and its securities with the assistance of your legal, tax and financial advisor.
▪ If the Information states that its securities are consistent with the future economic trends or even if your independent research indicates as such, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that Publisher is unable to predict; (c) human and social factors may outweigh future economic trends that Publisher states may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in such economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of fully new circumstances and situations in which uncertainty becomes reality rather than of predictive economic quality; or (f) if the trends involve a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.
▪ The Information contains forward-looking statements, i.e., statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as expects, will, anticipates, and estimates; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Issuers with the assistance of your lawyer, tax advisor and investment advisor as well as any such forward-looking statements. Any forward-looking statements made in the Information are limited to the time period in which they are made, and the Publisher does not undertake to update forward-looking statements that may change at any time.
▪ The Information is presented only as a brief snapshot of the Issuers and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Issuers and its securities and to consult your financial, legal or other advisor(s) and avail yourself of the filings and information that may be accessed at www.sec.gov or other electronic medium, including: (a) reviewing Information and Disclosure Statements and unaudited financial reports filed with the www.otcmarkets.com; (b) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (c) investment guides at www.sec.gov and www.finra.org. You should always be concerned that the Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative signs at otcmarkets.com. You should only invest with the assistance of your attorney, lawyer and tax advisor after they have conducted exhaustive due diligence on the particular Issuer and its trading activity.
▪ The Publisher may hire third-party service providers and stock promoters to electronically disseminate live news about the Issuers, yet the Publisher has no control over the content of and does not verify the information that these service providers publish.
The Publisher or its officers, directors, owners, managers, affiliates and control persons were paid to publish the Information about the issuers identified below:
Name of Issuer: 3rd party on behalf of Imunon, Inc
Amount of Cash Compensation: twenty two thousand five hundred usd
Period of Publication of Information: One day campaign beginning and ending on July twenty first twenty twenty six
Where Information is Published: MicroCapAlerts.io Website, Email Campaign, SMS Campaign, Social Media including but not limited to: Youtube, X, Tiktok, Instagram, Stock Twits, Reddit, Discord.
By reading the Information and visiting the Platform, you agree you have not relied on the Information and agree to indemnify, defend and hold the Publisher harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to your receipt of the Information without limitation.
Leave a Reply